Ophthalmology stories

Jun 24, 2026

Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.

Jun 24, 2026·2 sources

Apr 8, 2026

Smart Contact Lens Monitors Eye Pressure and Delivers Glaucoma Drugs in Preclinical Tests

Researchers at the Terasaki Institute for Biomedical Innovation developed a smart contact lens that combines real-time intraocular pressure monitoring with responsive drug delivery for glaucoma patients, showing promise in preclinical models.

Apr 8, 2026·2 sources

Virus from Seafood Jumps to Humans, Causing Chronic Eye Disease

A virus that typically infects marine animals such as shrimp and fish has jumped to humans and is causing chronic eye disease in some people, according to a study published in Nature Microbiology.

Apr 8, 2026·1 source

Top claims

▪The Series B round was oversubscribed and was one of the largest for a biotech company in the last two years.
▪The funding will also advance OLN102, a drug for thyroid eye disease and Graves' disease, into human testing in 2026.
▪OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD).

Topics

Clinical trials Lyme disease treatment Texas Wearables & health tracking Biomarkers & bloodwork testing

Related entities

Zoonotic disease China

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources